Neoplasm of uncertain behavior of unspecified ovary
ICD-10 D39.10 is a billable code used to indicate a diagnosis of neoplasm of uncertain behavior of unspecified ovary.
D39.10 refers to a neoplasm of uncertain behavior located in the ovary, where the specific nature of the tumor is not definitively classified as benign or malignant. Neoplasms of uncertain behavior can present a diagnostic challenge, as they may exhibit characteristics that suggest potential malignancy but do not meet the criteria for a definitive malignant diagnosis. These tumors may arise from various cell types within the ovary and can vary in their growth patterns and potential for progression. Surveillance is critical in managing these cases, as the risk of progression to malignancy can vary significantly based on histological features and patient factors. Regular monitoring through imaging and clinical evaluations is essential to detect any changes in the tumor's behavior. The management of patients with D39.10 often involves a multidisciplinary approach, including gynecologists, oncologists, and pathologists, to ensure appropriate follow-up and intervention if necessary.
Detailed descriptions of tumor characteristics, imaging results, and follow-up plans.
Initial diagnosis of an ovarian mass, follow-up imaging for tumor growth, and management of patients with uncertain behavior tumors.
Ensure clear documentation of the tumor's behavior and any changes noted during follow-up visits.
Comprehensive treatment plans, histopathology reports, and ongoing surveillance documentation.
Consultation for potential malignancy, treatment planning for neoplasms of uncertain behavior, and monitoring for progression.
Collaboration with pathologists for accurate histological classification and documentation of treatment response.
Used when a patient with D39.10 undergoes surgical intervention for an ovarian mass.
Operative report detailing the procedure and findings.
Ensure that the diagnosis aligns with the surgical procedure performed.
It refers to a tumor that cannot be definitively classified as benign or malignant based on current clinical and pathological information.
Patients should be monitored regularly, typically every 3-6 months, depending on the tumor's characteristics and clinical judgment.
